Predicting tumor response to anti-ERBB3 antibodies

US9828635B2 · kind B2 · utility

Assignee

• AVEO Pharmaceuticals, Inc. · US

Inventors

• Sylvie Vincent · Somerville, US
• Kristan Meetze · Lexington, US
• Bin Feng · Beijing, CN
• Steven Tyler · Boston, US
• Steve Bottega · Cambridge, US
• Richard Nicoletti · Lanesborough, US
• Donna McIntosh · Chelmsford, US
• Jeno Gyuris · Lincoln, US

Key dates

• Filing date: Oct 5, 2012
• Grant date: Nov 28, 2017
• Expiry date: Oct 5, 2032

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2800/52
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A diagnostic method for predicting quantitatively whether a human tumor will be sensitive or resistant to treatment with an ERBB3 inhibitor, e.g, an anti-ERBB3 antibody, is disclosed. The method is based on measurement of NRG1 expression at the RNA level, or at the protein level, in a tissue sample from the tumor.